Shares of Momenta Pharmaceuticals, Inc. (MNTA) have traded between $9.52 – 31.9. The next earnings date is set for Feb 28, 2020. Let’s see how its prospects are shaping up.

What does Momenta Pharmaceuticals, Inc.(MNTA) do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

MNTA Insider Trading Insight

On 2019-12-24, Fier Ian Chief Mfg, Program Officer sold 39,133 shares of MNTA. That represents a value of $1,182. Not to be outdone, on 2019-12-24, Manning Anthony M. S – Sale+OE sold51,445 shares of MNTA. These insiders are clearly in the know because they work closely with the company.

The WSBC Consensus Price Target

The mean recommendation of WesBanco, Inc. from top Wall Street analysts is a Hold. That is based on 1 analysts who work on the Street. Based on 1 analyst offering 12 month price targets for WesBanco in the last 3 months. The average price target is $38.00 with a high forecast of $38.00 and a low forecast of $38.00. The average price target represents a 4.68% increase from the last price of $36.30. Last week, several articles were published in financial papers about WSBC and 37% Bearish while 63% Bullish.

WSBC Intraday Trading

WSBC is due to report earnings on Jan 27, 2020. In the last year the price has ranged from 33.19 – 43.14. Recently, Crawford Michael J. sold 10,000 shares of WSBC. He is a $171,583 shareholder in WSBC.

Looking for stocks similar to MNTA and WSBC?

Here are some stocks to consider: